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Homozygous variegate porphyria is a severe skin and
neurologic disease manifesting in early infancy, and char-
acterized by markedly reduced levels of the penultimate
enzyme in the heme biosynthetic pathway, protoporphyr-
inogen oxidase. We investigated the molecular basis of
variegate porphyria, usually an autosomal dominantly
inherited trait, in a severely affected female proband and
her parents. The mutation detection strategy included
heteroduplex analysis, automated sequencing, and allele
specific oligonucleotide hybridization. We identified two
The porphyrias are disorders of heme metabolism resultingfrom the inherited or acquired dysregulation of one ofthe eight enzymes that control the porphyrin-hemebiosynthetic pathway. Variegate porphyria (VP), one ofthe acute hepatic porphyrias, is characterized by a partial
defect in the activity of protoporphyrinogen oxidase (PPO), the
penultimate enzyme in the heme biosynthetic pathway (Frank and
Christiano, 1997).
VP is usually inherited as an autosomal dominant trait, displaying
incomplete penetrance, as not all persons carrying a mutation in the
PPO gene develop the clinical phenotype (Frank and Christiano, 1997).
In heterozygotes, PPO activity is decreased by µ50%. Homozygous VP
is a very rare recessive disease, presenting with residual PPO levels
between 5 and 20%, and to date only a few cases have been reported
(Kordac et al, 1984; Murphy et al, 1986; Mustajoki et al, 1987; Norris
et al, 1990; Coakley et al, 1990; Gandolfo et al, 1991; Hift et al, 1993).
Clinically, VP is characterized by cutaneous manifestations, including
increased photosensitivity, blistering, skin fragility with chronic scarring
of sun-exposed areas, and postinflammatory hyperpigmentation (Dean,
1971). Acute exacerbations of VP include abdominal pain, the passage
of dark urine, and neuropsychiatric symptoms that characterize the
acute hepatic porphyrias, such as bulbar paralysis, quadriplegia, motor
neuropathy, and weakness of the limbs (Frank and Christiano, 1997).
In heterozygotes, the disease does not usually present before puberty
(Coakley et al, 1990), whereas homozygous patients develop severe
symptoms in early infancy (Hift et al, 1993).
The human PPO cDNA and gene were recently cloned and mapped
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underlying missense mutations in the protoporphyrin-
ogen oxidase gene, consisting of a G-to-A transition in
exon 6 (G169E), and a G-to-A transition in exon 10
(G358R). Our study establishes the molecular basis of
‘‘homozygous’’ variegate porphyria for the first time, in
demonstrating that this patient is a compound hetero-
zygote for two different missense mutations in the proto-
porphyrinogen oxidase gene. Key words: genodermatosis/
photosensitivity/porphyria/porphyrin-heme biosynthetic path-
way. J Invest Dermatol 110:452–455, 1998
to chromosome 1q22–23 (Nishimura et al, 1995; Roberts et al, 1995;
Taketani et al, 1995a), and we and others have recently identified
pathogenetic mutations in several families with VP (Deybach et al,
1996; Meissner et al, 1996; Warnich et al, 1996; Lam et al, 1997; Frank
and Christiano, 1997). In this study, we investigated a proband who
was diagnosed with ‘‘homozygous’’ VP in 1989 (Norris et al, 1990),
and her clinically unaffected parents. We identified a G-to-A transition
in exon 6 and a G-to-A transition in exon 10 of the PPO gene,
resulting in the substitution of glycine by glutamic acid (G169E) on
the paternal PPO allele, and glycine by arginine (G358R) on the
maternal allele, respectively. Our study establishes, for the first time,
that this patient is a compound heterozygote for two different missense
mutations in the PPO gene and thereby offers a molecular explanation
for the autosomal recessive ‘‘homozygous’’ form of VP.
MATERIALS AND METHODS
Probands and controls The patient, her parents, and 50 unrelated unaffected
controls were investigated in this study. Diagnosis of VP in the patient was
established by one of us (J.L.M. Hawk) in a previously published investigation
(Norris et al, 1990). The now 20 y old female proband was the daughter of
nonconsanguineous parents with no family history of porphyria.
Clinical material Blood samples from the proband (Fig 1A) and her
parents were collected in tubes containing ethylenediamine tetraacetic acid. All
individuals provided informed consent for inclusion in the investigation, in
accordance with guidelines set forth by the local institutional review board.
Genomic DNA was isolated according to standard techniques (Sambrook
et al, 1989).
Polymerase chain reaction (PCR) amplification and mutation
detection A mutation detection strategy was developed for PCR amplification
of all PPO exons using PCR primers that were published recently (Warnich
et al, 1996). For amplification of exon 6 of the PPO gene, the following primers
were used: PPO exon 6L, 59GGGCTGTGGAAATCAGTCAG39; and PPO
exon 6R, 59TTCACCCTCTGAATCGATCC39. For amplification of exon
10 of the PPO gene, the following primers were used: PPO exon 10L,
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Figure 1. Mutation analysis in the VP patient in this study and her
family members. (A) Clinical findings in the patient on sun-exposed area;
erosions, crusts, superficial scars, perioral radial linear scarring. (B) Heteroduplex
analysis of the family and a control (C); heteroduplex formation in the proband
(P) and her father (F) in exon 6, and the proband (P) and her mother (M) in
exon 10 of the PPO gene. (C) Automated sequence of the forward strands of
the PCR fragments of exon 6 and exon 10, respectively; G-to-A transition in
exon 6 of the proband (lower panel, indicated by an arrow) compared with the
control (upper panel), and G-to-A transition in exon 10 of the proband (lower
panel, indicated by an arrow) compared with the control (upper panel). (D)
Pedigree of the nuclear family; the proband (II/1) is indicated by a filled circle,
her parents (I/1 and I/2) are indicated by half-filled symbols. (E) ASO
hybridization results: in exon 6, the proband (P) and her father (F) show the
mutant allele G169E (lower panel) and the wild-type allele, whereas mother (M)
and control (C) only show wild-type allele (upper panel); in exon 10, proband
(P) and her mother (M) show the mutant allele G358R (lower panel) and the
wild-type allele, whereas father (F) and control (C) only show the wild-type
allele (upper panel).
59AGAGCCCTTTCCTTCTGACGCATG39; and PPO exon 10R, 59TGGC-
CTTGCCTACAATGGAGCAC39.
PCR was carried out on genomic DNA from all family members according
to the following program: 95°C for 10 min; followed by 40 cycles of 95°C for
45 s, 57°C for 45 s, and 72°C for 1 min; followed by 72°C for 15 min, in an
OmniGene thermal cycler (Marsh Scientific, Rochester, NY). For mutation
detection, PCR products were subjected to conformation sensitive gel electro-
phoresis (CSGE) analysis as described previously (Ganguly et al, 1993). PCR
products displaying a heteroduplex on CSGE analysis were sequenced automatic-
ally using an ABI Prism 310 Genetic Analyzer. To verify the mutations, allele
specific oligonucleotide hybridization was performed according to standard
techniques (Sambrook et al, 1989). In this case, the following oligonucleotides
were used: Oligo exon 6 mutant, 59TCTGCCGTGAAGTGTTTGCA39; and
Oligo exon 6 wild-type, 59TCTGCCGTGGAGTGTTTGC39. Oligo exon
10 mutant, 59AGCAGGACAGGAGCCCC39; and Oligo exon 10 wild-type,
59GCAGGACGGGAGCCCC39.
RESULTS
Heteroduplex analysis of exon 6 of the PPO gene in this family
revealed a heteroduplex in the proband and her father (Fig 1B).
Automated sequencing of the PCR product of exon 6 revealed a
similar sequence deviation in the proband and her father (Fig 1C).
The mutation consisted of a G-to-A transition at nucleotide 505 of
the PPO cDNA (numbered according to GenBank #D38537). This
base substitution leads to a missense mutation consisting of an amino
acid change from glycine to glutamic acid at position 169 (G169E) in
the deduced amino acid sequence on the paternal allele.
Heteroduplex analysis of exon 10 of the PPO gene in this family
revealed a heteroduplex in the proband and her mother (Fig 1B).
Automated sequence analysis of the PCR product of exon 10 showed
the same sequence variant in the proband and her mother (Fig 1C).
The mutation consisted of a G-to-A transition at nucleotide 1071 of
the PPO cDNA (numbered according to GenBank #D38537). This
Figure 2. (A) Alignment of deduced amino acid sequences from codons 161
to 180 in exon 6 of human PPO (hPPO), mouse PPO (mPPO), the Hem Y
gene product from Bacillus subtillis (hemY), and the yeast Saccharomyces cerevisiae
(SC hem 14). The identical residues in codon 169 and the substitution derived
from the described missense mutation are shaded and bold. (B) Alignment of
deduced amino acid sequences from codons 351 to 370 in exon 10 of human
PPO (hPPO) and mouse PPO (mPPO). The identical residues in codon 358
and the substitution derived from the described missense mutation are shaded
and bold.
base change results in a missense mutation causing an amino acid
substitution from glycine to arginine at position 358 (G358R) in the
deduced amino acid sequence on the maternal allele.
Heteroduplex analysis of exon 6 and exon 10 of the PPO gene was
also carried out in 50 unrelated control individuals and showed no
heteroduplex formation indicative of the mutation, suggesting that
these sequence variations are not common polymorphisms in the PPO
gene (data not shown).
To verify the sequence variations in exon 6 and exon 10, allele specific
oligonucleotide hybridization was performed (Fig 1E). Furthermore, all
remaining PPO exons of the patient and her parents were checked for
additional sequence variants but revealed no other mutations.
The proband revealed raised erythrocyte protoporphyrin levels with
the protoporphyrin being predominantly zinc-chelated (Norris et al,
1990) and PPO activity measured in Epstein–Barr virus transformed
lymphoblasts was decreased to less than 20%, whereas both parents had
approximately half-normal levels of PPO (Norris et al, 1990) (Table I).
DISCUSSION
Only 10 patients with the diagnosis of ‘‘homozygous’’ VP have been
reported (Kordac et al, 1984; Murphy et al, 1986; Mustajoki et al,
1987; Norris et al, 1990; Coakley et al, 1990; Gandolfo et al, 1991;
Hift et al, 1993), indicating that this variant of VP is very rare. These
10 cases were reported at a time when the genetic lesions in the PPO
gene were not yet identified, so that making a DNA based diagnosis
was not possible. Therefore, at that time, diagnosis of ‘‘homozygous’’
VP was made by the severe clinical findings in the patients and
biochemical analyses; however, Hift et al postulated in 1993 that some
of the cases of ‘‘homozygous’’ VP would be compound heterozygotes
rather than true homozygotes (Hift et al, 1993). In support of this
notion, our results demonstrate that the ‘‘homozygous’’ VP patient
reported by Norris et al (1990) is indeed a compound heterozygote.
Twelve mutations have been identified to date in the PPO gene
(Table II) (Deybach et al, 1996; Meissner et al, 1996; Warnich et al,
1996; Lam et al, 1997; Frank and Christiano, 1997). The paternal
mutation detected in this study is a G-to-A transition in exon 6 of the
PPO gene, designated G169E. Three lines of evidence support the
notion that this base substitution is responsible for VP in this severely
affected proband. First, it causes an amino acid change from a neutral
glycine residue to a negatively charged glutamic acid residue at position
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Table I. Results of measurement of porphyrins and their precursors in the patient’s urine, stool, erythrocytes lymphoblasts
according to Norris et al (1990)
Proband Father Mother Reference ranges
Urine
Uroporphyrin (µg per liter) 145 – – 0–18
Coproporphyrin (µg per liter) 184 – – 0–149
Stool
Coproporphyrin (µg per g dry weight) 131 8 13 0–30
Protoporphyrin (µg per g dry weight) 171 12 17 0–125
Ether insoluble (X) porphyrin (µg per dry weight) 332 5 5 0–20
Erythrocytes
Total porphyrin (µg per dl) 645 74 121 0–95
Lymphoblasts
PPO enzyme activity (nmol protoporphyrin per hour per mg protein) 0.06 0.28 0.29 0.38–0.47
Table II. Mutations in the PPO gene reported to date
Designation Location Consequence Reference
Dominant VP
1083delT exon 10 Frameshift mutation Frank and Christiano, 1997
165insAG exon 3 Frameshift mutation Lam et al, 1997
1144del GT exon 11 Frameshift mutation Frank and Christiano, 1997
1022insG exon 7 Frameshift mutation Deybach et al, 1996
S450P exon 13 Missense mutation Frank and Christiano, 1997
G232R exon 7 Missense mutation Deybach et al, 1996
H20P exon 2 Missense mutation Warnich et al, 1996
R59W exon 3 Missense mutation Meissner et al, 1996
Warnich et al, 1996
R168C exon 6 Missense mutation Meissner et al, 1996
Warnich et al, 1996
E133X exon 5 Nonsense mutation Frank et al, 1998
Recessive VP
G169E/G358R exon 6/exon 10 Compound heterozygote missense mutation This study
169 (G169E) on the paternal allele of the PPO gene that may destabilize
specific interactions in PPO and impair proper functioning of the
protein. Second, a comparison of deduced amino acid sequences
(Fig 2A) revealed this glycine residue to be strictly conserved through
evolution in human (Nishimura et al, 1995), mouse (Taketani et al,
1995b), Bacillus subtilis (Taketani et al, 1995b), and Saccharomyces cerevisiae
(Camadro and Labbe, 1996), although their entire amino acid sequence
identity is less than 20%. Third, no other deviation in the father’s
cDNA sequence of the PPO gene was detected.
The maternal mutation consisted of a G-to-A transition in exon 10
of the PPO gene, designated G358R. Because glycine is a neutral
amino acid whereas arginine is positively charged, this mutation is also
likely to cause disturbances and dysfunction of the protein. A compar-
ison of deduced amino acid sequences (Fig 2B) showed that this
glycine residue is conserved in human and mouse PPO, over 90
million evolutionary years. No other abnormality was found in the
coding sequence of the mother’s PPO gene.
Usually, VP is inherited in an autosomal dominant fashion (Frank
and Christiano, 1997). In this study, however, we demonstrated that
disease transmission in this family is clearly autosomal recessive. As
each parent carried one mutation and had a reduced enzymatic activity
(Table I), each of the mutations must reduce the activity of PPO;
however, family history did not reveal any clinical symptoms of VP.
It is not yet understood why some heterozygous carriers of mutations
in the PPO gene develop the clinical phenotype and others do not.
In this case, the affected proband was a compound heterozygote for
the mutations and revealed markedly reduced PPO activity (,20%)
and severe clinical symptoms (Norris et al, 1990). Thus, we postulate
that inheritance of two missense mutations leads to a profound
biochemical defect that predisposes to a severe phenotype with clinical
findings that are not present in heterozygous VP patients. The clinically
severe recessive form of VP described here has similarities to the
‘‘homozygous’’ forms of erythropoietic protoporphyria, hereditary
coproporphyria, and porphyria cutanea tarda reported previously
(Grandchamp et al, 1977; Elder et al, 1981; Goerz et al, 1994; Sarkany
and Cox, 1995). It appears that such a pattern of disease inheritance is
associated with a more severe clinical phenotype. Remarkably, only in
the reported cases with ‘‘homozygous’’ VP does the clinical phenotype
include mental retardation, hand deformities, developmental delay, and
nystagmus (Hift et al, 1993), presumably as a consequence of the
profound enzyme deficiency. We propose that probands with this
recessively inherited variant of VP are at high risk for the development
of more severe clinical findings.
Interestingly, only ‘‘homozygous’’ VP patients show elevated proto-
porphyrin levels in the erythrocytes, with the protoporphyrin being
predominantly zinc-chelated (Hift et al, 1993), whereas heterozygous
VP patients do not. This accumulation of protoporphyrin was also
reported in cases of homozygous porphyria cutanea tarda (Elder et al,
1981) and in homozygous hereditary coproporphyria (Nordmann et al,
1982), and appears to be a general consequence of severe enzymatic
defects in the porphyrin-heme biosynthetic pathway.
This study establishes the molecular basis of ‘‘homozygous’’ VP for
the first time. Further investigations are underway to elucidate the
molecular basis of VP, establish genotype-to-phenotype correlations by
the expression of mutant alleles, and understand additional and unusual
mechanisms of inheritance of the disease. These studies will provide
the basis for the design of enzyme-replacement strategies as a therapy
for VP in the future.
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